DA-5515 is developed by Dong-A Pharmaceutical.

What development phase is DA-5515 in?

DA-5515 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

DA-5515

Dong-A Pharmaceutical · FDA-approved active Small molecule Quality 6/100

DA-5515, marketed by Dong-A Pharmaceutical, is a small molecule with a specific mechanism of action, though its primary indication and revenue figures are not specified. The drug's key strength lies in its protected intellectual property, with the key composition patent expiring in 2028. The primary risk is the lack of detailed clinical trial results and competitor information, which may impact its market positioning and strategic planning.

At a glance

Generic name	DA-5515
Also known as	Circulan® Soft Capule
Sponsor	Dong-A Pharmaceutical
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DA-5515 CI brief — competitive landscape report
DA-5515 updates RSS · CI watch RSS
Dong-A Pharmaceutical portfolio CI